Barclays
WHWK icon

Barclays’s Whitehawk Therapeutics WHWK Stock Holding History

Barclays’s Portfolio WHWK Stock Details WHWK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$65.1K Buy
17,321
+10,888
+169% +$45.9K ﹤0.01% 4481
2026
Q2 		$29.5K Buy
6,433
+5,786
+894% +$24.1K ﹤0.01% 4499
2026
Q1 		$2.23K Buy
+647
New +$2.03K ﹤0.01% 4841
2024
Q3 		– Sell
-8
Closed -$11 – 5533
2024
Q2 		$11 Sell
8
-11,348
-100% -$21K ﹤0.01% 4789
2024
Q1 		$26.6K Sell
11,356
-10,905
-49% -$21K ﹤0.01% 4722
2023
Q4 		$45K Buy
22,261
+19,434
+687% +$81.5K ﹤0.01% 4790
2023
Q3 		$13.7K Sell
2,827
-401
-12% -$2.33K ﹤0.01% 4250
2023
Q2 		$22.1K Sell
3,228
-4,088
-56% -$31.8K ﹤0.01% 4116
2023
Q1 		$53K Buy
7,316
+3,428
+88% +$36.6K ﹤0.01% 4429
2022
Q4 		$49.9K Buy
3,888
+3,274
+533% +$42.7K ﹤0.01% 4553
2022
Q3 		$9K Sell
614
-326
-35% -$4.28K ﹤0.01% 4368
2022
Q2 		$12K Buy
+940
New +$14K ﹤0.01% 4581
2021
Q2 		– Sell
-777
Closed -$15K – 5118
2021
Q1 		$15K Buy
+777
New +$17.9K ﹤0.01% 4408

Other funds holding WHWK

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Los Angeles Capital Management
Los Angeles Capital Management Los Angeles, California $29.2B AUM 33.64% 1-Year Est. Return

Barclays's WHWK Position: Q3 2026 in Review

Barclays increased its Whitehawk Therapeutics (WHWK) stake by 169% in Q3 2026, buying an estimated $45.9K and bringing the position to 17,321 shares worth $65.1K. The position accounts for ﹤0.01% of the portfolio, ranked #4481.

Barclays first reported a position in WHWK in Q1 2021 and has held it in 13 quarters since. 32 funds tracked by Wall St. Rank hold WHWK as of Q3 2026.

  • Barclays held 17,321 shares of Whitehawk Therapeutics worth $65.1K as of Q3 2026.
  • Barclays bought 10,888 Whitehawk Therapeutics shares in Q3 2026, an estimated $45.9K.
  • Whitehawk Therapeutics made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #4481 holding.
  • Barclays first reported a position in Whitehawk Therapeutics in Q1 2021 and has held it in 13 quarters since.
  • 32 funds tracked by Wall St. Rank held Whitehawk Therapeutics as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.